cefepime + dexamethasone + meropenem + methylprednisolone + piperacillin + tazobactam + vancomycin

This is a combination regimen consisting of seven drugs commonly used in critical care and severe infection settings. The components are: - **Cefepime**: A fourth-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria, including *Pseudomonas aeruginosa*. It works by inhibiting bacterial cell wall synthesis[2][4]. - **Dexamethasone** and **Methylprednisolone**: Synthetic glucocorticoid corticosteroids that act as anti-inflammatory and immunosuppressive agents by binding to the glucocorticoid receptor, modulating gene expression, and suppressing pro-inflammatory cytokines. - **Meropenem**: A carbapenem-class beta-lactam antibiotic with very broad-spectrum antibacterial activity, including many multidrug-resistant organisms. It inhibits bacterial cell wall synthesis. - **Piperacillin + Tazobactam**: A combination of an extended-spectrum penicillin (piperacillin) that inhibits bacterial cell wall synthesis, plus a beta-lactamase inhibitor (tazobactam) that protects piperacillin from enzymatic degradation. This combination is used for serious infections caused by susceptible organisms[6][8][10]. - **Vancomycin**: A glycopeptide antibiotic effective primarily against Gram-positive bacteria; it inhibits cell wall biosynthesis. This multi-drug regimen may be used empirically in critically ill patients or those with suspected or confirmed severe polymicrobial infections, especially when multidrug-resistant pathogens are a concern.